A role for STEAP2 in prostate cancer progression

[1]  J. T. Trindade Filho,et al.  STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma , 2013, Histopathology.

[2]  K. Kamiguchi,et al.  Six-transmembrane epithelial antigen of the prostate-1 plays a role for in vivo tumor growth via intercellular communication. , 2013, Experimental cell research.

[3]  B. Klein,et al.  STEAP1 is overexpressed in cancers: a promising therapeutic target. , 2012, Biochemical and biophysical research communications.

[4]  C. Santos,et al.  STEAP Proteins: From Structure to Applications in Cancer Therapy , 2012, Molecular Cancer Research.

[5]  J. Heinze,et al.  Understanding tumor heterogeneity as functional compartments - superorganisms revisited , 2011, Journal of Translational Medicine.

[6]  C. Gialeli,et al.  Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting , 2011, The FEBS journal.

[7]  Valerie M. Weaver,et al.  The extracellular matrix at a glance , 2010, Journal of Cell Science.

[8]  Ling Wang,et al.  STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer. , 2010, Cancer research.

[9]  F. Saatcioglu,et al.  Dual specificity phosphatases in prostate cancer , 2009, Molecular and Cellular Endocrinology.

[10]  Michiel M T van Dommelen,et al.  Human Golgi antiapoptotic protein modulates intracellular calcium fluxes. , 2009, Molecular biology of the cell.

[11]  G. Murphy.  The ADAMs: signalling scissors in the tumour microenvironment , 2008, Nature Reviews Cancer.

[12]  S. Zucker,et al.  Membrane Type 1 Matrix Metalloproteinase Induces Epithelial-to-Mesenchymal Transition in Prostate Cancer* , 2008, Journal of Biological Chemistry.

[13]  M. Duffy,et al.  Cancer invasion and metastasis: changing views , 2008, The Journal of pathology.

[14]  F. Saatcioglu,et al.  Androgen signaling and its interactions with other signaling pathways in prostate cancer , 2007, BioEssays : news and reviews in molecular, cellular and developmental biology.

[15]  S. Kanner,et al.  Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. , 2007, Cancer research.

[16]  N. Prevarskaya,et al.  Ion channels in death and differentiation of prostate cancer cells , 2007, Cell Death and Differentiation.

[17]  Vincenza Dolo,et al.  Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. , 2007, Neoplasia.

[18]  P. Lange,et al.  Newer potential biomarkers in prostate cancer. , 2007, Reviews in urology.

[19]  C. Maley,et al.  Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .

[20]  M. Fleming,et al.  The Steap proteins are metalloreductases. , 2006, Blood.

[21]  L. Skoog,et al.  Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer. , 2004, Oncology reports.

[22]  K. Reddy,et al.  Role of MAP kinase in tumor progression and invasion , 2003, Cancer and Metastasis Reviews.

[23]  P. Abel,et al.  Molecular and cellular biology of prostate cancer , 1997, Cancer and Metastasis Reviews.

[24]  Jean M Harper,et al.  Voltage-gated Na+ channels confer invasive properties on human prostate cancer cells , 2004, Pflügers Archiv.

[25]  P. Kaplan,et al.  Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer , 2003, The Prostate.

[26]  S. Biesterfeld,et al.  Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue , 2003, Prostate Cancer and Prostatic Diseases.

[27]  M. Loda,et al.  Molecular Cloning and Characterization of STAMP1, a Highly Prostate-specific Six Transmembrane Protein that Is Overexpressed in Prostate Cancer* , 2002, The Journal of Biological Chemistry.

[28]  F. Bethencourt,et al.  Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate. , 2002, Human pathology.

[29]  A W Partin,et al.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.

[30]  V. Keshamouni,et al.  Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion , 2001, Oncogene.

[31]  M. Djamgoz,et al.  Voltage‐gated K+ channel activity in human prostate cancer cell lines of markedly different metastatic potential: Distinguishing characteristics of PC‐3 and LNCaP cells , 2001, The Prostate.

[32]  H. Frierson,et al.  Activation of mitogen-activated protein kinase associated with prostate cancer progression. , 1999, Cancer research.

[33]  S B Malkowicz,et al.  Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .

[34]  C. Foster,et al.  Sodium channel protein expression enhances the invasiveness of rat and human prostate cancer cells , 1998, FEBS letters.

[35]  P. Abel,et al.  Expression and functional analysis of voltage-activated Na+ channels in human prostate cancer cell lines and their contribution to invasion in vitro. , 1997, The American journal of pathology.